AZN vs. RHHVF: A Head-to-Head Stock Comparison
Here's a clear look at AZN and RHHVF, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | AZN | RHHVF |
|---|---|---|
| Company Name | AstraZeneca PLC | Roche Holding AG |
| Country | United Kingdom | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 311.93 billion USD | 335.44 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | OTC Markets OTCQX |
| Listing Date | May 12, 1993 | February 13, 2009 |
| Security Type | ADR | Common Stock |
AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RHHVF is a standard domestic listing.
AZN's market capitalization stands at 311.93 billion USD, while RHHVF's is 335.44 billion USD, indicating their market valuations are broadly comparable.
AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RHHVF is a standard domestic listing.
Historical Performance
This chart compares the performance of AZN and RHHVF by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AZN | RHHVF |
|---|---|---|
| 5-Day Price Return | -1.96% | 1.42% |
| 13-Week Price Return | 5.65% | -- |
| 26-Week Price Return | 16.49% | -- |
| 52-Week Price Return | 45.12% | -- |
| Month-to-Date Return | 1.55% | 2.07% |
| Year-to-Date Return | 8.18% | 1.52% |
| 10-Day Avg. Volume | 1.43M | 0.89M |
| 3-Month Avg. Volume | 1.31M | 1.01M |
| 3-Month Volatility | 26.01% | -- |
| Beta | 1.06 | 1.45 |
With betas of 1.06 for AZN and 1.45 for RHHVF, both stocks show similar sensitivity to overall market movements.
Profitability
Return on Equity (TTM)
AZN
22.68%
Pharmaceuticals Industry
- Max
- 39.28%
- Q3
- 20.55%
- Median
- 12.78%
- Q1
- 5.01%
- Min
- -14.55%
In the upper quartile for the Pharmaceuticals industry, AZN's Return on Equity of 22.68% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
RHHVF
--
Pharmaceuticals Industry
- Max
- 39.28%
- Q3
- 20.55%
- Median
- 12.78%
- Q1
- 5.01%
- Min
- -14.55%
Return on Equity data for RHHVF is currently unavailable.
Net Profit Margin (TTM)
AZN
17.41%
Pharmaceuticals Industry
- Max
- 36.97%
- Q3
- 20.13%
- Median
- 14.64%
- Q1
- 7.56%
- Min
- -8.35%
AZN's Net Profit Margin of 17.41% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
RHHVF
--
Pharmaceuticals Industry
- Max
- 36.97%
- Q3
- 20.13%
- Median
- 14.64%
- Q1
- 7.56%
- Min
- -8.35%
Net Profit Margin data for RHHVF is currently unavailable.
Operating Profit Margin (TTM)
AZN
23.40%
Pharmaceuticals Industry
- Max
- 43.61%
- Q3
- 25.42%
- Median
- 18.73%
- Q1
- 12.49%
- Min
- -4.35%
AZN's Operating Profit Margin of 23.40% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
RHHVF
--
Pharmaceuticals Industry
- Max
- 43.61%
- Q3
- 25.42%
- Median
- 18.73%
- Q1
- 12.49%
- Min
- -4.35%
Operating Profit Margin data for RHHVF is currently unavailable.
Profitability at a Glance
| Symbol | AZN | RHHVF |
|---|---|---|
| Return on Equity (TTM) | 22.68% | -- |
| Return on Assets (TTM) | 9.15% | -- |
| Net Profit Margin (TTM) | 17.41% | -- |
| Operating Profit Margin (TTM) | 23.40% | -- |
| Gross Profit Margin (TTM) | 81.31% | -- |
Financial Strength
Current Ratio (MRQ)
AZN
0.94
Pharmaceuticals Industry
- Max
- 6.33
- Q3
- 3.51
- Median
- 2.17
- Q1
- 1.39
- Min
- 0.80
AZN's Current Ratio of 0.94 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
RHHVF
--
Pharmaceuticals Industry
- Max
- 6.33
- Q3
- 3.51
- Median
- 2.17
- Q1
- 1.39
- Min
- 0.80
Current Ratio data for RHHVF is currently unavailable.
Debt-to-Equity Ratio (MRQ)
AZN
0.61
Pharmaceuticals Industry
- Max
- 1.60
- Q3
- 0.77
- Median
- 0.28
- Q1
- 0.04
- Min
- 0.00
AZN's Debt-to-Equity Ratio of 0.61 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RHHVF
--
Pharmaceuticals Industry
- Max
- 1.60
- Q3
- 0.77
- Median
- 0.28
- Q1
- 0.04
- Min
- 0.00
Debt-to-Equity Ratio data for RHHVF is currently unavailable.
Interest Coverage Ratio (TTM)
AZN
10.25
Pharmaceuticals Industry
- Max
- 154.61
- Q3
- 67.33
- Median
- 12.49
- Q1
- 2.53
- Min
- -27.02
AZN's Interest Coverage Ratio of 10.25 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
RHHVF
--
Pharmaceuticals Industry
- Max
- 154.61
- Q3
- 67.33
- Median
- 12.49
- Q1
- 2.53
- Min
- -27.02
Interest Coverage Ratio data for RHHVF is currently unavailable.
Financial Strength at a Glance
| Symbol | AZN | RHHVF |
|---|---|---|
| Current Ratio (MRQ) | 0.94 | -- |
| Quick Ratio (MRQ) | 0.72 | -- |
| Debt-to-Equity Ratio (MRQ) | 0.61 | -- |
| Interest Coverage Ratio (TTM) | 10.25 | -- |
Growth
Revenue Growth
Revenue Growth at a Glance
| Symbol | AZN | RHHVF |
|---|---|---|
| Revenue Growth (MRQ vs Prior YoY) | 4.11% | -- |
| Revenue Growth (TTM vs Prior YoY) | 8.63% | -- |
| 3-Year Revenue CAGR | 9.82% | -- |
| 5-Year Revenue CAGR | 17.15% | -- |
EPS Growth
EPS Growth at a Glance
| Symbol | AZN | RHHVF |
|---|---|---|
| EPS Growth (MRQ vs Prior YoY) | 55.36% | -- |
| EPS Growth (TTM vs Prior YoY) | 45.41% | -- |
| 3-Year EPS CAGR | 45.90% | -- |
| 5-Year EPS CAGR | 21.88% | -- |
Dividend
Dividend Yield (TTM)
AZN
1.59%
Pharmaceuticals Industry
- Max
- 6.29%
- Q3
- 2.93%
- Median
- 1.59%
- Q1
- 0.00%
- Min
- 0.00%
AZN's Dividend Yield of 1.59% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
RHHVF
0.00%
Pharmaceuticals Industry
- Max
- 6.29%
- Q3
- 2.93%
- Median
- 1.59%
- Q1
- 0.00%
- Min
- 0.00%
RHHVF currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
AZN
48.62%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 76.07%
- Median
- 43.56%
- Q1
- 0.00%
- Min
- 0.00%
AZN's Dividend Payout Ratio of 48.62% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
RHHVF
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 76.07%
- Median
- 43.56%
- Q1
- 0.00%
- Min
- 0.00%
RHHVF has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AZN | RHHVF |
|---|---|---|
| Dividend Yield (TTM) | 1.59% | 0.00% |
| Dividend Payout Ratio (TTM) | 48.62% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
AZN
30.66
Pharmaceuticals Industry
- Max
- 46.88
- Q3
- 30.69
- Median
- 19.24
- Q1
- 14.01
- Min
- 3.78
AZN's P/E Ratio of 30.66 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RHHVF
--
Pharmaceuticals Industry
- Max
- 46.88
- Q3
- 30.69
- Median
- 19.24
- Q1
- 14.01
- Min
- 3.78
P/E Ratio data for RHHVF is currently unavailable.
Price-to-Sales Ratio (TTM)
AZN
5.34
Pharmaceuticals Industry
- Max
- 7.61
- Q3
- 5.34
- Median
- 2.48
- Q1
- 1.99
- Min
- 0.21
AZN's P/S Ratio of 5.34 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RHHVF
--
Pharmaceuticals Industry
- Max
- 7.61
- Q3
- 5.34
- Median
- 2.48
- Q1
- 1.99
- Min
- 0.21
P/S Ratio data for RHHVF is currently unavailable.
Price-to-Book Ratio (MRQ)
AZN
5.93
Pharmaceuticals Industry
- Max
- 10.12
- Q3
- 5.22
- Median
- 2.61
- Q1
- 1.54
- Min
- 0.63
AZN's P/B Ratio of 5.93 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company's net assets, a valuation that hinges on its ability to generate superior profits.
RHHVF
--
Pharmaceuticals Industry
- Max
- 10.12
- Q3
- 5.22
- Median
- 2.61
- Q1
- 1.54
- Min
- 0.63
P/B Ratio data for RHHVF is currently unavailable.
Valuation at a Glance
| Symbol | AZN | RHHVF |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 30.66 | -- |
| Price-to-Sales Ratio (TTM) | 5.34 | -- |
| Price-to-Book Ratio (MRQ) | 5.93 | -- |
| Price-to-Free Cash Flow Ratio (TTM) | 36.16 | -- |